MAP2K7 and cancer: Analysis of IC50s for growth inhibition across multiple cell lines shows that when compared to KRAS-wild type cells, KRAS-mutant cell lines are most sensitive to MEK inhibitors compared to inhibitors of other cancer-associated pathways8.